:    O
PhMgBr    B-Bromide114785625
+    O
Te    O
→    O
PhTeMgBr    O

In    O
1926    O
T.    O
Weichselfelder    O
and    O
B.    O
Thiede    O
claimed    O
to    O
have    O
prepared    O
solid    O
chromium    O
trihydride    O
by    O
reacting    O
hydrogen    O
with    O
chromium    O
chloride    O
and    O
phenylmagnesium    B-Bromide114785625
bromide    I-Bromide114785625
in    O
ether    O
,    O
forming    O
a    O
black    O
precipitate    O
.    O

151    O
°C    O
,    O
8    O
mm    O
Hg    O
)    O
via    O
reaction    O
with    O
phenylmagnesium    B-Bromide114785625
bromide    I-Bromide114785625
followed    O
by    O
methanolysis    O
.    O

Best    O
known    O
in    O
organic    O
chemistry    O
is    O
diphenyldiselenide    O
,    O
prepared    O
from    O
phenylmagnesium    B-Bromide114785625
bromide    I-Bromide114785625
and    O
selenium    O
followed    O
by    O
oxidation    O
of    O
the    O
product    O
PhSeMgBr    O
.    O

Many    O
Grignard    O
reagents    O
such    O
as    O
methylmagnesium    O
bromide    O
,    O
methylmagnesium    O
chloride    O
,    O
phenylmagnesium    B-Bromide114785625
bromide    I-Bromide114785625
,    O
and    O
allylmagnesium    O
bromide    O
are    O
available    O
commercially    O
as    O
tetrahydrofuran    O
or    O
diethyl    O
ether    O
solutions    O
.    O

Clidinium    B-Bromide114785625
bromide    I-Bromide114785625
(    O
INN    O
)    O
is    O
an    O
anticholinergic    O
(    O
specifically    O
a    O
muscarinic    O
antagonist    O
)    O
drug    O
.    O

Cerium(III)    B-Bromide114785625
bromide    I-Bromide114785625
is    O
an    O
inorganic    O
compound    O
with    O
the    O
formula    O
CeBr3    O
.    O

Timepidium    B-Bromide114785625
bromide    I-Bromide114785625

Treatment    O
of    O
that    O
with    O
cyanogen    B-Bromide114785625
bromide    I-Bromide114785625
under    O
von    O
Braun    O
reaction    O
conditions    O
leads    O
to    O
the    O
isolable    O
aminocyanide    O
.    O

The    O
Institute    O
of    O
Forensic    O
Medicine    O
at    O
the    O
University    O
of    O
Berne    O
made    O
a    O
statement    O
,    O
based    O
on    O
a    O
Red    O
Cross    O
report    O
,    O
that    O
the    O
gas    O
was    O
likely    O
to    O
have    O
been    O
halogenous    O
derivatives    O
-    O
phosgene    O
,    O
mustard    O
gas    O
,    O
lewisite    O
,    O
chloride    O
or    O
cyanogen    B-Bromide114785625
bromide    I-Bromide114785625
.    O

Cyanogen    B-Bromide114785625
bromide    I-Bromide114785625

Von    O
Braun    O
reaction    O
with    O
BrCN    B-Bromide114785625
(    O
or    O
ethyl    O
chloroformate    O
)    O
followed    O
by    O
saponification    O
of    O
the    O
intermediate    O
leads    O
to    O
the    O
2°    O
amine    O
(    O
6    O
)    O
.    O

Platinum    B-Bromide114785625
bromide    I-Bromide114785625
is    O
the    O
chemical    O
compound    O
with    O
the    O
formula    O
PtBr2    O
.    O

With    O
halogens    O
,    O
yttrium    O
forms    O
trihalides    O
such    O
as    O
yttrium(III    O
)    O
fluoride    O
,    O
yttrium(III    O
)    O
chloride    O
,    O
and    O
yttrium(III)    B-Bromide114785625
bromide    I-Bromide114785625
at    O
temperatures    O
above    O
roughly    O
200    O
°C    O
.    O

Bibenzonium    B-Bromide114785625
bromide    I-Bromide114785625
is    O
a    O
cough    O
suppressant    O
.    O

Oxyphenonium    B-Bromide114785625
bromide    I-Bromide114785625
is    O
an    O
antimuscarinic    O
.    O

In    O
1881    O
,    O
the    O
Russian    O
chemist    O
Mikhail    O
Kucherov    O
described    O
the    O
hydration    O
of    O
acetylene    O
to    O
acetaldehyde    O
using    O
catalysts    O
such    O
as    O
mercury(II)    B-Bromide114785625
bromide    I-Bromide114785625
.    O

FeBr2ñ    B-Bromide114785625
,    O

MgBr2    B-Bromide114785625
,    O
TiBr2    O
,    O
VBr2    B-Bromide114785625
,    O
MnBr2    B-Bromide114785625
,    O
FeBr2    B-Bromide114785625
,    O
CoBr2    B-Bromide114785625
.    O

MgBr2    B-Bromide114785625
,    O
TiBr2    O
,    O
VBr2    B-Bromide114785625
,    O
MnBr2    B-Bromide114785625
,    O
FeBr2    B-Bromide114785625
,    O
CoBr2    B-Bromide114785625
.    O

YbBr3    B-Bromide114785625
,    O

Alcohols    O
may    O
likewise    O
be    O
converted    O
to    O
bromoalkanes    O
using    O
hydrobromic    O
acid    O
or    O
phosphorus    B-Bromide114785625
tribromide    I-Bromide114785625
(    O
PBr3    O
)    O
.    O

Phosphorus    B-Bromide114785625
tribromide    I-Bromide114785625

For    O
example    O
,    O
the    O
commercially    O
significant    O
bromoacetic    O
acid    O
is    O
generated    O
directly    O
from    O
acetic    O
acid    O
and    O
bromine    O
in    O
the    O
presence    O
of    O
phosphorus    B-Bromide114785625
tribromide    I-Bromide114785625
catalyst    O
:    O

Propargyl    O
bromide    O
may    O
be    O
produced    O
by    O
the    O
treatment    O
of    O
propargyl    O
alcohol    O
with    O
phosphorus    B-Bromide114785625
tribromide    I-Bromide114785625
.    O

Scandium    B-Bromide114785625
bromide    I-Bromide114785625
,    O
or    O
ScBr3    O
,    O
is    O
a    O
trihalide    O
,    O
hygroscopic    O
,    O
water    O
-    O
soluble    O
chemical    O
compound    O
of    O
scandium    O
and    O
bromine    O
.    O

=    O
=    O
=    O
Indium(III)    B-Bromide114785625
bromide    I-Bromide114785625

Disulfur    B-Bromide114785625
dibromide    I-Bromide114785625

Copper(II)    B-Bromide114785625
bromide    I-Bromide114785625
,    O
CuBr2    O

An    O
example    O
of    O
this    O
salt    O
mediated    O
bromide    O
displacement    O
is    O
the    O
use    O
of    O
Copper(II)    B-Bromide114785625
bromide    I-Bromide114785625
on    O
ketones    O
:    O

HgF4    O
is    O
isoelectronic    O
with    O
the    O
tetrafluoroaurate    O
anion    O
,    O
,    O
and    O
is    O
valence    O
isoelectronic    O
with    O
the    O
tetrachloroaurate    O
,    O
tetrabromoaurate    B-Bromide114785625
,    O
and    O
tetrachloroplatinate    O
anions    O
.    O

CdBr2    B-Bromide114785625
,    O

Benzododecinium    B-Bromide114785625
bromide    I-Bromide114785625
(    O
systematic    O
name    O
dimethyldodecylbenzylammonium    B-Bromide114785625
bromide    I-Bromide114785625
)    O
is    O
a    O
quaternary    O
ammonium    O
compound    O
used    O
as    O
antiseptic    O
and    O
disinfectant    O
(    O
phenol    O
coefficient    O
is    O
20    O
-    O
30    O
)    O
.    O

Certain    O
crystals    O
,    O
typically    O
doped    O
with    O
rare    O
-    O
earth    O
ions    O
(    O
e.g.    O
neodymium    O
,    O
ytterbium    O
,    O
or    O
erbium    O
)    O
or    O
transition    O
metal    O
ions    O
(    O
titanium    O
or    O
chromium    O
)    O
;    O
most    O
often    O
yttrium    O
aluminium    O
garnet    O
(    O
Y3Al5O12    O
)    O
,    O
yttrium    O
orthovanadate    O
(    O
YVO4    O
)    O
,    O
or    O
sapphire    O
(    O
Al2O3    O
)    O
;    O
and    O
not    O
often    O
Caesium    B-Bromide114785625
cadmium    I-Bromide114785625
bromide    I-Bromide114785625
(    O
CsCdBr3    O
)    O

(    O
or    O
lanthanum    B-Bromide114785625
bromide    I-Bromide114785625
doped    O
with    O
cerium    O
)    O
:    O
a    O
better    O
(    O
novel    O
)    O
alternative    O
to    O
;    O
denser    O
,    O
more    O
efficient    O
,    O
much    O
faster    O
(    O
having    O
a    O
decay    O
time    O
about    O
~20ns    O
)    O
,    O
offers    O
superior    O
energy    O
resolution    O
due    O
to    O
its    O
very    O
high    O
light    O
output    O
.    O

The    O
compound    O
is    O
created    O
by    O
the    O
recovery    O
of    O
hydrogen    O
from    O
vanadium(III)    B-Bromide114785625
bromide    I-Bromide114785625
.    O

Cetrimonium    B-Bromide114785625
bromide    I-Bromide114785625
-    O
An    O
C19    O
structural    O
analogue    O

Surfactants    O
that    O
have    O
been    O
used    O
include    O
cetrimonium    B-Bromide114785625
bromide    I-Bromide114785625
,    O
cetyltrimethylammonium    O
chloride    O
,    O
and    O
glycerol    O
.    O

Cetrimonium    B-Bromide114785625
bromide    I-Bromide114785625
,    O
a    O
compound    O
related    O
to    O
miltefosine    O
,    O
was    O
demonstrated    O
in    O
2007    O
to    O
exhibit    O
potent    O
"    O
in    O
vitro    O
"    O
activity    O
against    O
"    O
Plasmodium    O
falciparum    O
"    O
.    O

Other    O
experiments    O
have    O
used    O
sodium    O
iodide    O
,    O
scandium    O
iodide    O
,    O
indium    B-Bromide114785625
monobromide    I-Bromide114785625
(    O
InBr    O
)    O
,    O
or    O
tellurium    O
as    O
the    O
light    O
-    O
generating    O
medium    O
.    O

Tetraethyltin    O
can    O
be    O
obtained    O
by    O
reacting    O
ethylmagnesium    B-Bromide114785625
bromide    I-Bromide114785625
with    O
tin(IV    O
)    O
chloride    O
:    O

Fentonium    B-Bromide114785625
is    O
a    O
belladonna    O
derivative    O
.    O

The    O
melting    O
point    O
of    O
SnF4    O
is    O
much    O
higher    O
(    O
700    O
°C    O
)    O
than    O
the    O
other    O
tin(IV    O
)    O
halides    O
which    O
are    O
relatively    O
low    O
melting    O
,    O
(    O
SnCl4    O
,    O
−33.3    O
°C    O
;    O
SnBr4    B-Bromide114785625
,    O
31    O
°C    O
;    O
SnI4    O
,    O
144    O
°C    O
)    O
.    O

When    O
the    O
same    O
mixture    O
is    O
heated    O
to    O
150    O
°C    O
,    O
one    O
obtains    O
the    O
metastable    O
monoclinic    O
phase    O
β-TeI.    O
The    O
compounds    O
are    O
related    O
structurally    O
to    O
Te2I    O
(    O
see    O
ditellurium    B-Bromide114785625
bromide    I-Bromide114785625
)    O
,    O
but    O
the    O
additional    O
iodide    O
groups    O
do    O
not    O
bridge    O
to    O
other    O
Te    O
centers    O
.    O

It    O
is    O
purified    O
by    O
extracting    O
with    O
absolute    O
diethyl    O
ether    O
to    O
remove    O
any    O
CrBr2    B-Bromide114785625
,    O
and    O
is    O
subsequently    O
washed    O
with    O
absolute    O
diethyl    O
ether    O
and    O
absolute    O
ethanol    O
.    O

Tellurium    B-Bromide114785625
tetrabromide    I-Bromide114785625
,    O
TeBr4    O

Bromide    O
ions    O
,    O
as    O
provided    O
by    O
salts    O
like    O
sodium    B-Bromide114785625
bromide    I-Bromide114785625
,    O
function    O
as    O
a    O
nucleophiles    O
in    O
the    O
formation    O
of    O
organobromine    O
compounds    O
by    O
displacement    O
.    O

Mercury(I    O
)    O
bromide    O
is    O
prepared    O
by    O
the    O
oxidation    O
of    O
elemental    O
mercury    O
with    O
elemental    O
bromine    O
or    O
by    O
adding    O
sodium    B-Bromide114785625
bromide    I-Bromide114785625
to    O
a    O
solution    O
of    O
mercury(I    O
)    O
nitrate    O
.    O

:    O
C8H17Br(org    O
)    O
+    O
NaCN(aq    O
)    O
→    O
C8H17CN(org    O
)    O
+    O
NaBr    B-Bromide114785625
)    O
(    O
catalyzed    O
by    O
a    O
R4P+Br−    O
PTC    O
)    O

This    O
reaction    O
forms    O
bromine    O
azide    O
and    O
sodium    B-Bromide114785625
bromide    I-Bromide114785625
:    O

Molybdenum(II)    B-Bromide114785625
bromide    I-Bromide114785625
is    O
an    O
inorganic    O
compound    O
with    O
the    O
formula    O
MoBr2    O
.    O

PBr5    B-Bromide114785625
,    O

Pyridostigmine    B-Bromide114785625

Myasthenia    O
gravis    O
is    O
generally    O
treated    O
with    O
medications    O
known    O
as    O
acetylcholinesterase    O
inhibitors    O
such    O
as    O
neostigmine    O
and    O
pyridostigmine    B-Bromide114785625
.    O

Pyridostigmine    B-Bromide114785625
is    O
a    O
relatively    O
long    O
-    O
acting    O
drug    O
(    O
when    O
compared    O
to    O
other    O
cholinergic    O
agonists    O
)    O
,    O
with    O
a    O
half    O
-    O
life    O
around    O
four    O
hours    O
with    O
relatively    O
few    O
side    O
effects    O
.    O

In    O
the    O
1960s    O
smaller    O
scale    O
experiments    O
took    O
place    O
with    O
non    O
-    O
lethal    O
agents    O
such    O
as    O
LSD    O
and    O
glycollates    O
,    O
and    O
more    O
recently    O
testing    O
focused    O
on    O
countermeasures    O
such    O
as    O
pyridostigmine    B-Bromide114785625
bromide    I-Bromide114785625
which    O
is    O
a    O
pre    O
-    O
treatment    O
for    O
nerve    O
agents    O
.    O

Gold(III)    B-Bromide114785625
bromide    I-Bromide114785625
is    O
a    O
dark    O
-    O
red    O
to    O
black    O
crystalline    O
solid    O
.    O

The    O
thionyl    O
halides    O
should    O
not    O
be    O
confused    O
with    O
"    O
thionylan    O
"    O
and    O
include    O
thionyl    O
fluoride    O
,    O
thionyl    O
chloride    O
,    O
and    O
thionyl    B-Bromide114785625
bromide    I-Bromide114785625
.    O
"    O

Thionyl    O
chloride    O
and    O
thionyl    B-Bromide114785625
bromide    I-Bromide114785625
have    O
similar    O
structures    O
,    O
although    O
these    O
compounds    O
are    O
liquid    O
at    O
room    O
temperature    O
.    O

NH4Br    B-Bromide114785625
,    O

This    O
structure    O
is    O
shared    O
with    O
CsBr    B-Bromide114785625
and    O
CsI    O
and    O
many    O
binary    O
metallic    O
alloys    O
.    O

Lithium    B-Bromide114785625
bromide    I-Bromide114785625
(    O
LiBr    B-Bromide114785625
)    O
is    O
a    O
chemical    O
compound    O
of    O
lithium    O
and    O
bromine    O
.    O

The    O
single    O
-    O
effect    O
absorption    O
cycle    O
uses    O
water    O
as    O
the    O
refrigerant    O
and    O
lithium    B-Bromide114785625
bromide    I-Bromide114785625
as    O
the    O
absorbent    O
.    O

Lithium    O
borohydride    O
may    O
be    O
prepared    O
by    O
the    O
metathesis    O
reaction    O
,    O
which    O
occurs    O
upon    O
ball    O
-    O
milling    O
the    O
more    O
commonly    O
available    O
sodium    O
borohydride    O
,    O
and    O
lithium    B-Bromide114785625
bromide    I-Bromide114785625
:    O

For    O
example    O
,    O
the    O
compound    O
LiBr    O
is    O
made    O
of    O
Li+    O
cations    O
and    O
Br−    O
anions    O
;    O
thus    O
,    O
it    O
's    O
called    O
lithium    B-Bromide114785625
bromide    I-Bromide114785625
.    O

Propantheline    B-Bromide114785625
bromide    I-Bromide114785625
(    O
INN    O
)    O
is    O
an    O
antimuscarinic    O
agent    O
used    O
for    O
the    O
treatment    O
of    O
excessive    O
sweating    O
(    O
hyperhidrosis    O
)    O
,    O
cramps    O
or    O
spasms    O
of    O
the    O
stomach    O
,    O
intestines    O
(    O
gut    O
)    O
or    O
bladder    O
,    O
and    O
involuntary    O
urination    O
(    O
enuresis    O
)    O
.    O

Propantheline    B-Bromide114785625
bromide    I-Bromide114785625
(    O
Pro    O
-    O
Banthine    O
)    O

-    O
thiol    O
(    O
maleimide    O
,    O
acetyl    B-Bromide114785625
bromide    I-Bromide114785625
)    O

Niobium(V)    B-Bromide114785625
bromide    I-Bromide114785625
is    O
the    O
inorganic    O
compound    O
with    O
the    O
formula    O
Nb2Br10    O
.    O

Deuterium    B-Bromide114785625
bromide    I-Bromide114785625
is    O
hydrogen    O
bromide    O
with    O
the    O
hydrogen    O
being    O
the    O
heavier    O
isotope    O
deuterium    O
.    O

Mukaiyama    O
employed    O
in    O
his    O
rendition    O
of    O
taxol    O
total    O
synthesis    O
(    O
1999    O
)    O
two    O
aldol    O
additions    O
,    O
one    O
with    O
an    O
ketene    O
silyl    O
acetal    O
and    O
excess    O
magnesium    B-Bromide114785625
bromide    I-Bromide114785625
:    O

A    O
Mukaiyama    O
aldol    O
addition    O
(    O
magnesium    B-Bromide114785625
bromide    I-Bromide114785625
/    O
toluene    O
)    O
took    O
place    O
between    O
aldehyde    O
7    O
and    O
ketene    O
silyl    O
acetal    O
8    O
with    O
71%    O
stereoselectivity    O
to    O
alcohol    O
9    O
which    O
was    O
protected    O
as    O
the    O
TBS    O
ether    O
10    O
(    O
TBSOTf    O
,    O
2,6-lutidine    O
)    O
.    O

Nickel(II)    B-Bromide114785625
bromide    I-Bromide114785625
is    O
the    O
name    O
for    O
the    O
inorganic    O
compounds    O
with    O
the    O
chemical    O
formula    O
NiBr2(H2O)x    O
.    O

Pipecuronium    B-Bromide114785625

Uranium    B-Bromide114785625
pentabromide    I-Bromide114785625
is    O
an    O
inorganic    O
chemical    O
compound    O
.    O

TbBr3    B-Bromide114785625
,    O

Perflubron    B-Bromide114785625
,    O
a    O
type    O
of    O
perfluorocarbon    O
,    O
has    O
been    O
used    O
as    O
a    O
gastrointestinal    O
MRI    O
contrast    O
agent    O
for    O
pediatric    O
imaging    O
.    O

Mercury(I)    B-Bromide114785625
bromide    I-Bromide114785625
or    O
mercurous    B-Bromide114785625
bromide    I-Bromide114785625
is    O
the    O
chemical    O
compound    O
composed    O
of    O
mercury    O
and    O
bromine    O
with    O
the    O
formula    O
Hg2Br2    O
.    O

Protection    O
:    O
Potassium    O
hydride    O
,    O
tetra    O
-    O
n    O
-    O
butylammonium    O
iodide    O
,    O
and    O
benzyl    B-Bromide114785625
bromide    I-Bromide114785625
.    O

In    O
another    O
development    O
,    O
Anet    O
and    O
Leblanc    O
also    O
in    O
1957    O
prepared    O
a    O
benzyl    O
chromium    O
solution    O
from    O
benzyl    B-Bromide114785625
bromide    I-Bromide114785625
and    O
chromium(II    O
)    O
perchlorate    O
.    O

In    O
this    O
case    O
,    O
the    O
cyanide    O
anion    O
is    O
the    O
synthetic    O
equivalent    O
for    O
the    O
COOH−    O
synthon    O
,    O
while    O
benzyl    B-Bromide114785625
bromide    I-Bromide114785625
is    O
the    O
synthetic    O
equivalent    O
for    O
the    O
benzyl    O
synthon    O
.    O

Boron    B-Bromide114785625
tribromide    I-Bromide114785625
is    O
a    O
classical    O
reagent    O
for    O
the    O
dealkylation    O
of    O
methyl    O
arylethers    O
.    O

Some    O
ethers    O
undergo    O
rapid    O
cleavage    O
with    O
boron    B-Bromide114785625
tribromide    I-Bromide114785625
(    O
even    O
aluminium    O
chloride    O
is    O
used    O
in    O
some    O
cases    O
)    O
to    O
give    O
the    O
alkyl    O
bromide    O
.    O

The    O
first    O
documented    O
artificially    O
irradiated    O
gemstone    O
was    O
created    O
by    O
English    O
chemist    O
Sir    O
William    O
Crookes    O
in    O
1905    O
,    O
by    O
burying    O
a    O
diamond    O
in    O
powdered    O
radium    B-Bromide114785625
bromide    I-Bromide114785625
.    O

Rutherford    O
used    O
alpha    O
particles    O
emitted    O
by    O
radium    B-Bromide114785625
bromide    I-Bromide114785625
to    O
infer    O
that    O
J.    O
J.    O
Thomson    O
's    O
Plum    O
pudding    O
model    O
of    O
the    O
atom    O
was    O
fundamentally    O
flawed    O
.    O

HSiBr3    B-Bromide114785625
,    O

The    O
low    O
temperature    O
structure    O
is    O
similar    O
to    O
that    O
of    O
molybdenum    B-Bromide114785625
tribromide    I-Bromide114785625
.    O

BeBr2    B-Bromide114785625
,    O

The    O
term    O
"    O
bromide    O
"    O
can    O
also    O
refer    O
to    O
a    O
bromine    O
atom    O
with    O
an    O
oxidation    O
number    O
of    O
−1    O
in    O
covalent    O
compounds    O
such    O
as    O
sulfur    B-Bromide114785625
dibromide    I-Bromide114785625
(    O
SBr2    O
)    O
.    O

Oxitropium    B-Bromide114785625
(    O
Oxivent    O
)    O

Solid    O
is    O
dimeric    O
,    O
consisting    O
of    O
,    O
similar    O
to    O
that    O
of    O
AlBr3    B-Bromide114785625
.    O

The    O
monomer    O
,    O
is    O
trigonal    O
planar    O
with    O
a    O
bond    O
length    O
of    O
2.448(6    O
)    O
Å    O
,    O
and    O
the    O
bridged    O
dimer    O
,    O
at    O
430    O
K    O
is    O
a    O
similar    O
to    O
Al2Cl6    O
and    O
Al2Br6    B-Bromide114785625
with    O
bond    O
lengths    O
of    O
2.456(6    O
)    O
Å    O
(    O
terminal    O
)    O
and    O
2.670(8    O
)    O
Å    O
(    O
bridging    O
)    O
.    O

Bromoform    O
can    O
be    O
prepared    O
by    O
the    O
haloform    O
reaction    O
using    O
acetone    O
and    O
sodium    O
hypobromite    O
,    O
by    O
the    O
electrolysis    O
of    O
potassium    O
bromide    O
in    O
ethanol    O
,    O
or    O
by    O
treating    O
chloroform    O
with    O
aluminium    B-Bromide114785625
bromide    I-Bromide114785625
.    O

MgBr2    B-Bromide114785625
,    O
TiBr2    O
,    O
VBr2    B-Bromide114785625
,    O
MnBr2    B-Bromide114785625
,    O
FeBr2    B-Bromide114785625
,    O
CoBr2    B-Bromide114785625
.    O

Uranium    B-Bromide114785625
tetrabromide    I-Bromide114785625
is    O
an    O
inorganic    O
chemical    O
compound    O
of    O
uranium    O
in    O
oxidation    O
state    O
+    O
4    O
.    O

It    O
is    O
used    O
to    O
relieve    O
spasmodic    O
pain    O
of    O
the    O
gut    O
especially    O
irritable    O
bowel    O
syndrome    O
and    O
is    O
sold    O
under    O
the    O
trade    O
name    O
Spasmoctyl    B-Bromide114785625
40    I-Bromide114785625
,    O
and    O
as    O
Doralin    B-Bromide114785625
in    O
Greece    O
.    O

NOBr    B-Bromide114785625
,    O

Antimony    O
trichloride    O
is    O
prepared    O
by    O
reaction    O
of    O
chlorine    O
with    O
antimony    O
,    O
antimony    B-Bromide114785625
tribromide    I-Bromide114785625
,    O
antimony    O
trioxide    O
,    O
or    O
antimony    O
trisulfide    O
.    O

AuCl    O
,    O
AuBr    B-Bromide114785625
,    O
and    O
AuI    O
are    O
all    O
crystalline    O
solids    O
with    O
a    O
structure    O
containing    O
alternating    O
linear    O
chains    O
:    O
..    O
-X    O
-    O
Au    O
-    O
X    O
-    O
Au    O
-    O
X    O
-    O
Au    O
-    O
X-    O
...    O

Glycopyrronium    B-Bromide114785625
bromide    I-Bromide114785625
is    O
a    O
medication    O
of    O
the    O
muscarinic    O
anticholinergic    O
group    O
.    O

The    O
cation    O
,    O
which    O
is    O
the    O
active    O
moiety    O
,    O
is    O
called    O
glycopyrronium    B-Bromide114785625
(    O
INN    O
)    O
or    O
glycopyrrolate    B-Bromide114785625
(    O
USAN    O
)    O
.    O

The    O
secretions    O
may    O
be    O
controlled    O
using    O
drugs    O
such    O
as    O
scopolamine    O
(    O
hyoscine    O
)    O
,    O
glycopyrronium    B-Bromide114785625
,    O
or    O
atropine    O
.    O

Glycopyrrolate    B-Bromide114785625
(    O
Robinul    O
)    O

Vanadium(II)    B-Bromide114785625
bromide    I-Bromide114785625
,    O
also    O
known    O
as    O
vanadium    O
dibromide    O
,    O
is    O
a    O
chemical    O
compound    O
with    O
the    O
formula    O
VBr2    O
.    O

At    O
moderate    O
temperatures    O
the    O
halogen    O
reacts    O
with    O
the    O
evaporating    O
tungsten    O
,    O
the    O
halide    B-Bromide114785625
formed    O
being    O
moved    O
around    O
in    O
the    O
inert    O
gas    O
filling    O
.    O

Sulfur    O
lamp    O
bulbs    O
with    O
calcium    B-Bromide114785625
bromide    I-Bromide114785625
(    O
CaBr2    O
)    O
added    O
produce    O
a    O
similar    O
spectrum    O
plus    O
a    O
spike    O
in    O
red    O
wavelengths    O
at    O
625    O
nm    O
.    O

Evidence    O
does    O
not    O
support    O
the    O
use    O
of    O
cimetropium    B-Bromide114785625
bromide    I-Bromide114785625
,    O
and    O
there    O
is    O
little    O
evidence    O
for    O
alternative    O
medications    O
or    O
techniques    O
.    O

demecarium    B-Bromide114785625
bromide    I-Bromide114785625
(    O
INN    O
)    O

adopts    O
similar    O
structures    O
to    O
TiBr4    B-Bromide114785625
and    O
TiI4    O
;    O
the    O
three    O
compounds    O
share    O
many    O
similarities    O
.    O
TiCl4    O
and    O

In    O
the    O
reaction    O
of    O
methyl    B-Bromide114785625
bromide    I-Bromide114785625
and    O
cyanide    O
(    O
shown    O
in    O
the    O
introduction    O
)    O
,    O
the    O
observed    O
methyl    O
carbon    O
kinetic    O
isotope    O
effect    O
indicates    O
an    O
SN2    O
mechanism    O
.    O

The    O
most    O
pervasive    O
is    O
the    O
naturally    O
produced    O
bromomethane    B-Bromide114785625
.    O

Methyl    B-Bromide114785625
bromide    I-Bromide114785625
,    O
another    O
fumigant    O
,    O
is    O
generated    O
from    O
methanol    O
and    O
hydrogen    O
bromide    O
.    O

Methyl    B-Bromide114785625
bromide    I-Bromide114785625
is    O
also    O
an    O
effective    O
fumigant    O
,    O
but    O
its    O
production    O
and    O
use    O
are    O
controlled    O
by    O
the    O
Montreal    O
Protocol    O
.    O

In    O
2014    O
,    O
Khon    O
Kaen    O
University    O
concluded    O
after    O
a    O
study    O
,    O
that    O
Thailand    O
should    O
ban    O
155    O
types    O
of    O
pesticides    O
,    O
with    O
14    O
listed    O
as    O
urgent    O
:    O
Carbofuran    O
,    O
Methyl    B-Bromide114785625
Bromide    I-Bromide114785625
,    O
Dichlorvos    O
,    O
Lambda    O
-    O
cyhalothrin    O
,    O
Methidathion    O
-    O
methyl    O
,    O
Omethoate    O
,    O
Zeta    O
Cypermethrin    O
,    O
Endosulfan    O
sulfate    O
,    O
Aldicarb    O
,    O
Azinphos    O
-    O
methyl    O
,    O
Chlorpyrifos    O
-    O
ethyl    O
,    O
Methoxychlor    O
and    O
Paraquat    O
.    O

reading    O
;    O
this    O
one    O
is    O
from    O
bromomethane    B-Bromide114785625
(    O
CH3Br    O
)    O
,    O
showing    O
peaks    O
around    O
3000    O
,    O
1300    O
,    O
and    O
1000    O
cm−1    O
(    O
on    O
the    O
horizontal    O
axis    O
)    O
.    O

3D    O
animation    O
of    O
the    O
symmetric    O
stretching    O
of    O
the    O
C    O
–    O
H    O
bonds    O
of    O
bromomethane    B-Bromide114785625
.    O

In    O
terms    O
of    O
raw    O
materials    O
the    O
C20    O
framework    O
is    O
built    O
up    O
from    O
L    O
-    O
serine    O
(    O
C3    O
)    O
,    O
isobutyric    O
acid    O
(    O
C4    O
)    O
,    O
glycolic    O
acid    O
(    O
C2    O
)    O
,    O
methyl    B-Bromide114785625
bromide    I-Bromide114785625
(    O
C1    O
)    O
,    O
methyl    O
iodide    O
(    O
C1    O
)    O
,    O
2,3-dibromopropene    O
(    O
C3    O
)    O
,    O
acetic    O
acid    O
(    O
C2    O
)    O
and    O
homoallyl    O
bromide    O
(    O
C4    O
)    O
.    O

Included    O
in    O
these    O
are    O
methanol    O
,    O
nitroglycerine    O
,    O
nitrocellulose    O
,    O
dimethylnitrosamine    O
,    O
and    O
the    O
halogenated    O
hydrocarbons    O
:    O
methyl    O
chloride    O
,    O
methyl    B-Bromide114785625
bromide    I-Bromide114785625
,    O
trichloroethylene    O
,    O
carbon    O
tetrachloride    O
,    O
and    O
the    O
chlorinated    O
naphthalenes    O
.    O

The    O
ecological    O
benefits    O
of    O
the    O
program    O
are    O
manifold    O
;    O
in    O
addition    O
to    O
reducing    O
pesticide    O
use    O
in    O
the    O
US    O
,    O
the    O
fumigation    O
of    O
exported    O
U.S.    O
cotton    O
bales    O
with    O
methyl    B-Bromide114785625
bromide    I-Bromide114785625
has    O
also    O
been    O
significantly    O
reduced    O
.    O

CBr4    B-Bromide114785625
,    O

The    O
common    O
carbon    O
halides    O
are    O
carbon    O
tetrafluoride    O
(    O
CF4    O
)    O
,    O
carbon    O
tetrachloride    O
(    O
CCl4    O
)    O
,    O
carbon    B-Bromide114785625
tetrabromide    I-Bromide114785625
(    O
CBr4    O
)    O
,    O
carbon    O
tetraiodide    O
(    O
CI4    O
)    O
,    O
and    O
a    O
large    O
number    O
of    O
other    O
carbon    O
-    O
halogen    O
compounds    O
.    O

Phosphorus    B-Bromide114785625
heptabromide    I-Bromide114785625
,    O
PBr7    O

;    O
GaCl3    O
,    O
GaBr3    B-Bromide114785625
and    O
GaI3    O

#    O
Morphine    B-Bromide114785625
methobromide    I-Bromide114785625

In    O
the    O
oxidized    O
zone    O
,    O
ore    O
minerals    O
include    O
native    O
silver    O
and    O
argentite    O
have    O
been    O
replaced    O
by    O
cerargyrite    O
,    O
iodobromite    O
,    O
bromyrite    B-Bromide114785625
,    O
embolite    O
,    O
iodyrite    B-Bromide114785625
.    O

With    O
chloride    O
sources    O
,    O
AsCl3    O
,    O
forms    O
salts    O
containing    O
the    O
anion    O
[    O
AsCl4]−.    O
Reaction    O
with    O
potassium    O
bromide    O
and    O
potassium    O
iodide    O
give    O
arsenic    B-Bromide114785625
tribromide    I-Bromide114785625
and    O
arsenic    O
triiodide    O
,    O
respectively    O
.    O

In    O
oxidation    O
state    O
+    O
3    O
,    O
bismuth    O
forms    O
trihalides    O
with    O
all    O
of    O
the    O
halogens    O
:    O
,    O
,    O
,    O
and    O
.    O

Bromopentaamminecobalt(III)    B-Bromide114785625
bromide    I-Bromide114785625
is    O
the    O
dibromide    O
salt    O
of    O
the    O
cobalt    O
coordination    O
compound    O
with    O
the    O
formula    O
[    O
Co(NH3)5Br]2    O
+    O
It    O
is    O
a    O
purple    O
,    O
water    O
-    O
soluble    O
solid    O
.    O

SYBR    O
Safe    O
is    O
a    O
safer    O
alternative    O
to    O
the    O
known    O
mutagen    O
ethidium    B-Bromide114785625
bromide    I-Bromide114785625
.    O

DNA    O
as    O
well    O
as    O
RNA    O
are    O
normally    O
visualized    O
by    O
staining    O
with    O
ethidium    B-Bromide114785625
bromide    I-Bromide114785625
,    O
which    O
intercalates    O
into    O
the    O
major    O
grooves    O
of    O
the    O
DNA    O
and    O
fluoresces    O
under    O
UV    O
light    O
.    O

The    O
gel    O
with    O
UV    O
illumination    O
:    O
DNA    O
stained    O
with    O
ethidium    B-Bromide114785625
bromide    I-Bromide114785625
appears    O
as    O
glowing    O
orange    O
bands    O
.    O

To    O
visualize    O
PCR    O
product    O
,    O
load    O
onto    O
1%agarose    O
gel    O
with    O
1x    O
sodium    O
borate    O
buffer    O
at    O
220    O
V    O
,    O
and    O
stain    O
with    O
ethidium    B-Bromide114785625
bromide    I-Bromide114785625
(    O
1    O
μg    O
ml−1    O
)    O

E.    O
coli    O
-    O
electrophoresis    O
-    O
electroporation    O
-    O
Ellis    O
-    O
van    O
Creveld    O
syndrome    O
-    O
end    O
labeling    O
-    O
endonuclease    O
-    O
enhancer    O
-    O
enzyme    O
-    O
epitope    O
-    O
ethidium    B-Bromide114785625
bromide    I-Bromide114785625
-    O
evolutionary    O
clock    O
-    O
evolutionary    O
footprinting    O
-    O
exon    O
-    O
exonuclease    O
-    O
expression    O
-    O
expression    O
clone    O
-    O
expression    O
vector    O
-    O

One    O
of    O
the    O
most    O
common    O
dyes    O
used    O
for    O
markers    O
is    O
ethidium    B-Bromide114785625
bromide    I-Bromide114785625
.    O

Gel    O
conditions    O
are    O
1%    O
agarose    O
,    O
3    O
volt    O
/    O
cm    O
,    O
and    O
ethidium    B-Bromide114785625
bromide    I-Bromide114785625
stain    O
.    O

The    O
multidrug    O
efflux    O
transporter    O
NorM    O
from    O
"    O
V.    O
parahaemolyticus    O
"    O
which    O
mediates    O
resistance    O
to    O
multiple    O
antimicrobial    O
agents    O
(    O
norfloxacin    O
,    O
kanamycin    O
,    O
ethidium    B-Bromide114785625
bromide    I-Bromide114785625
etc    O
.    O
)    O
and    O
its    O
homologue    O
from    O
"    O
E.    O
coli    O
"    O
were    O
identified    O
in    O
1998    O
.    O

The    O
most    O
popular    O
has    O
long    O
been    O
agarose    O
gel    O
electrophoresis    O
with    O
ethidium    B-Bromide114785625
bromide    I-Bromide114785625
staining    O
,    O
allowing    O
one    O
to    O
visualize    O
the    O
bands    O
from    O
the    O
rRNA    O
peaks    O
.    O

ZrBr4    B-Bromide114785625
,    O

Lead(II)    B-Bromide114785625
bromide    I-Bromide114785625
is    O
the    O
inorganic    O
compound    O
with    O
the    O
formula    O
PbBr2    O
.    O

SiBr4    B-Bromide114785625
,    O

For    O
example    O
,    O
bromopentacarbonylrhenium    B-Bromide114785625
can    O
be    O
converted    O
to    O
the    O
more    O
labile    O
derivative    O
using    O
silver    O
triflate    O
:    O

SnBr2    B-Bromide114785625
,    O

Water    O
-    O
soluble    O
dyes    O
,    O
such    O
as    O
ANNINE-6plus    B-Bromide114785625
,    O
do    O
not    O
suffer    O
this    O
problem    O
.    O

FeBr3    B-Bromide114785625
,    O

FeBr3    B-Bromide114785625
,    O

A    O
similar    O
dye    O
,    O
"    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
"    O
,    O
which    O
is    O
purple    O
-    O
red    O
in    O
color    O
,    O
was    O
made    O
from    O
a    O
related    O
species    O
of    O
marine    O
snail    O
,    O
"    O
Murex    O
brandaris    O
"    O
.    O

Tyrian    B-Bromide114785625
purple    I-Bromide114785625

The    O
tyrian    B-Bromide114785625
purple    I-Bromide114785625
,    O
which    O
is    O
a    O
dibromoindigo    O
,    O
is    O
representative    O
of    O
the    O
bromides    O
,    O
while    O
the    O
thyroxine    O
secreted    O
from    O
the    O
thyroid    O
gland    O
,    O
is    O
an    O
iodide    O
,    O
and    O
the    O
highly    O
toxic    O
fluoroacetate    O
is    O
one    O
of    O
the    O
rare    O
organofluorides    O
.    O

The    O
first    O
halocarbon    O
commercially    O
used    O
was    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
a    O
natural    O
organobromide    O
of    O
the    O
"    O
Murex    O
brandaris    O
"    O
marine    O
snail    O
.    O

In    O
the    O
Roman    O
Empire    O
the    O
colour    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
,    O
produced    O
with    O
an    O
extremely    O
expensive    O
Mediterranean    O
mollusk    O
extract    O
,    O
was    O
in    O
principle    O
reserved    O
for    O
the    O
Imperial    O
Court    O
.    O

The    O
naturally    O
occurring    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
(    O
6,6’-dibromoindigo    O
)    O
was    O
a    O
valued    O
dye    O
before    O
the    O
development    O
of    O
the    O
synthetic    O
dye    O
industry    O
in    O
the    O
late    O
19th    O
century    O
.    O

From    O
left    O
:    O
bromoform    O
,    O
a    O
brominated    O
bisphenol    O
,    O
dibromoindigo    O
(    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
)    O
,    O
and    O
the    O
antifeedant    O
tambjamine    O
B.    O

The    O
school    O
color    O
is    O
royal    B-Bromide114785625
purple    I-Bromide114785625
.    O

First    O
came    O
the    O
chemical    O
attestation    O
of    O
the    O
earliest    O
Royal    O
or    O
Tyrian    B-Bromide114785625
Purple    I-Bromide114785625
,    O
the    O
famous    O
dye    O
of    O
the    O
seafaring    O
Phoenicians    O
,    O
demonstrating    O
that    O
ancient    O
organic    O
compounds    O
(    O
specifically    O
,    O
6,6'-dibromoindigotin    O
)    O
could    O
survive    O
over    O
3000    O
years    O
.    O

The    O
dye    O
was    O
obtained    O
from    O
the    O
Murex    O
snail    O
and    O
dubbed    O
"    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
"    O
.    O

Plutarch    O
reports    O
that    O
Antony    O
covered    O
Brutus    O
'    O
body    O
with    O
a    O
purple    B-Bromide114785625
garment    O
as    O
a    O
sign    O
of    O
respect    O
,    O
as    O
they    O
had    O
been    O
friends    O
.    O

Zeno    O
confirmed    O
the    O
status    O
of    O
the    O
Church    O
of    O
Cyprus    O
and    O
granted    O
its    O
Archbishop    O
the    O
"    O
three    O
privileges    O
"    O
:    O
namely    O
to    O
sign    O
his    O
name    O
in    O
an    O
ink    O
made    O
vermilion    O
by    O
the    O
addition    O
of    O
cinnabar    O
;    O
to    O
wear    O
tyrian    B-Bromide114785625
purple    I-Bromide114785625
instead    O
of    O
black    O
robes    O
under    O
his    O
vestments    O
;    O
and    O
to    O
hold    O
an    O
imperial    O
sceptre    O
(    O
i.e.    O
a    O
gilt    O
staff    O
of    O
silver    O
,    O
topped    O
by    O
a    O
gold    O
globus    O
cruciger    O
)    O
instead    O
of    O
the    O
regular    O
episcopal    O
crosier    O
.    O

Dor    O
was    O
the    O
most    O
southern    O
settlement    O
of    O
the    O
Phoenicians    O
on    O
the    O
coast    O
of    O
Syria    O
and    O
a    O
center    O
for    O
the    O
manufacture    O
of    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
,    O
extracted    O
from    O
the    O
murex    O
snail    O
found    O
there    O
in    O
abundance    O
.    O

Excavations    O
at    O
Tel    O
Dor    O
in    O
1986    O
unearthed    O
an    O
intact    O
purple    B-Bromide114785625
dye    I-Bromide114785625
manufacturing    O
installation    O
,    O
based    O
on    O
dye    O
extracted    O
from    O
murex    O
marine    O
snails    O
.    O

It    O
was    O
the    O
birthplace    O
of    O
the    O
purple    O
dye    O
known    O
as    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
and    O
had    O
founded    O
several    O
colonies    O
in    O
the    O
Mediterranean    O
such    O
as    O
Carthage    O
and    O
Cadiz    O
.    O

The    O
club    O
's    O
home    O
colours    O
are    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
and    O
gold    O
,    O
which    O
gives    O
Roma    O
their    O
nickname    O
"    O
"    O
I    O
Giallorossi    O
"    O
"    O
(    O
"    O
The    O
Yellow    O
and    O
Reds    O
"    O
)    O
.    O

Roma    O
's    O
colours    O
of    O
imperial    B-Bromide114785625
purple    I-Bromide114785625
with    O
a    O
golden    O
yellow    O
trim    O
represents    O
the    O
traditional    O
colours    O
of    O
Rome    O
,    O
the    O
official    O
seal    O
of    O
the    O
Comune    O
di    O
Roma    O
features    O
the    O
same    O
colours    O
.    O

The    O
ancient    O
Phoenicians    O
not    O
only    O
exploited    O
numerous    O
fisheries    O
within    O
this    O
current    O
zone    O
,    O
but    O
also    O
established    O
a    O
factory    O
at    O
Iles    O
Purpuraires    O
off    O
present    O
day    O
Essaouira    O
for    O
extracting    O
a    O
Tyrian    B-Bromide114785625
purple    I-Bromide114785625
dye    O
from    O
a    O
marine    O
gastropod    O
murex    O
species    O
.    O

AEK    O
's    O
traditional    O
away    O
colours    O
are    O
all    O
-    O
black    O
or    O
all    O
-    O
white    O
;    O
on    O
a    O
few    O
occasions    O
,    O
the    O
club    O
has    O
introduced    O
as    O
a    O
third    O
kit    O
a    O
light    O
blue    O
,    O
a    O
silver    O
,    O
and    O
even    O
a    O
dark    O
red    O
,    O
or    O
a    O
tyrian    B-Bromide114785625
purple    I-Bromide114785625
(    O
"    O
porphyra    O
"    O
)    O
,    O
a    O
type    O
of    O
reddish    O
purple    O
,    O
inspired    O
by    O
the    O
war    O
Byzantine    O
flag    O
and    O
used    O
also    O
by    O
the    O
imperial    O
dynasties    O
of    O
the    O
Byzantine    O
empire    O
(    O
Eastern    O
Roman    O
empire    O
)    O
.    O

In    O
the    O
oxidized    O
zone    O
,    O
ore    O
minerals    O
include    O
native    O
silver    O
and    O
argentite    O
have    O
been    O
replaced    O
by    O
cerargyrite    O
,    O
iodobromite    O
,    O
bromyrite    B-Bromide114785625
,    O
embolite    O
,    O
iodyrite    B-Bromide114785625
.    O

Barium    B-Bromide114785625
bromide    I-Bromide114785625
is    O
the    O
chemical    O
compound    O
with    O
the    O
formula    O
BaBr2    O
.    O

It    O
consists    O
of    O
aclidinium    B-Bromide114785625
bromide    I-Bromide114785625
,    O
a    O
long    O
-    O
acting    O
muscarinic    O
antagonist    O
,    O
and    O
formoterol    O
,    O
a    O
long    O
-    O
acting    O
β2    O
agonist    O
.    O

The    O
synthesis    O
of    O
the    O
D    O
ring    O
(    O
"    O
scheme    O
6    O
"    O
)    O
started    O
from    O
44    O
with    O
allylic    O
bromination    O
with    O
copper(I)    B-Bromide114785625
bromide    I-Bromide114785625
and    O
benzoyl    O
tert    O
-    O
butyl    O
peroxide    O
to    O
bromide    O
45    O
.    O

Thus    O
,    O
phenylcopper    O
is    O
prepared    O
by    O
reaction    O
of    O
phenyllithium    O
with    O
copper(I)    B-Bromide114785625
bromide    I-Bromide114785625
in    O
diethyl    O
ether    O
.    O

These    O
polymers    O
are    O
made    O
through    O
oxidative    O
coupling    O
of    O
substituted    O
phenol    O
in    O
the    O
presence    O
of    O
oxygen    O
and    O
copper    O
and    O
amine    O
containing    O
catalysts    O
,    O
such    O
as    O
cuprous    B-Bromide114785625
bromide    I-Bromide114785625
and    O
pyridine    O
.    O

The    O
primary    O
method    O
of    O
execution    O
in    O
the    O
US    O
is    O
via    O
lethal    O
injection    O
which    O
generally    O
involves    O
the    O
administration    O
of    O
three    O
drugs    O
:    O
sodium    O
thiopental    O
,    O
a    O
sedative    O
to    O
induce    O
unconsciousness    O
,    O
pancuronium    B-Bromide114785625
bromide    I-Bromide114785625
(    O
Pavulon    O
)    O
,    O
a    O
muscle    O
relaxant    O
to    O
cause    O
respiratory    O
arrest    O
,    O
and    O
potassium    O
chloride    O
to    O
trigger    O
cardiac    O
arrest    O
.    O

Pancuronium    B-Bromide114785625

They    O
paralyze    O
him    O
for    O
the    O
procedure    O
with    O
pancuronium    B-Bromide114785625
.    O

One    O
contained    O
saline    O
,    O
another    O
contained    O
a    O
sleep    O
-    O
inducing    O
barbiturate    O
called    O
sodium    O
thiopental    O
and    O
the    O
third    O
a    O
lethal    O
mixture    O
of    O
potassium    O
chloride    O
,    O
which    O
immediately    O
stopped    O
the    O
heart    O
,    O
and    O
pancuronium    B-Bromide114785625
bromide    I-Bromide114785625
,    O
a    O
paralytic    O
medication    O
to    O
prevent    O
spasms    O
during    O
the    O
dying    O
process    O
.    O

Its    O
potential    O
adjunctive    O
use    O
in    O
anesthesia    O
to    O
facilitate    O
endotracheal    O
intubation    O
and    O
to    O
provide    O
skeletal    O
muscle    O
relaxation    O
during    O
surgery    O
or    O
mechanical    O
ventilation    O
was    O
briefly    O
evaluated    O
in    O
clinical    O
studies    O
in    O
India    O
,    O
but    O
further    O
development    O
discontinued    O
because    O
of    O
attendant    O
cardiovasular    O
effects    O
,    O
primarily    O
tachycardia    O
that    O
was    O
no    O
worse    O
than    O
but    O
also    O
not    O
an    O
improvement    O
over    O
the    O
clinically    O
established    O
pancuronium    B-Bromide114785625
bromide    I-Bromide114785625
.    O

The    O
"    O
mono"-    O
and    O
"    O
bis    O
"-    O
quaternary    O
azasteroid    O
series    O
of    O
compounds    O
to    O
which    O
candocuronium    O
belongs    O
are    O
based    O
on    O
the    O
same    O
principle    O
that    O
led    O
to    O
aminosteroids    O
such    O
as    O
pancuronium    B-Bromide114785625
,    O
vecuronium    B-Bromide114785625
and    O
rocuronium    O
:    O
use    O
of    O
the    O
steroid    O
skeleton    O
to    O
provide    O
a    O
somewhat    O
rigid    O
distance    O
between    O
the    O
two    O
quaternary    O
ammonium    O
centers    O
,    O
with    O
appendages    O
incorporating    O
fragments    O
of    O
choline    O
or    O
acetylcholine    O
.    O

hexafluronium    B-Bromide114785625
bromide    I-Bromide114785625
(    O
INN    O
)    O

Astatine    O
monobromide    O
is    O
produced    O
by    O
the    O
reaction    O
of    O
astatine    O
with    O
an    O
aqueous    O
solution    O
of    O
iodine    B-Bromide114785625
monobromide    I-Bromide114785625
:    O

domiphen    B-Bromide114785625
bromide    I-Bromide114785625
(    O
INN    O
)    O

bromazepam    B-Bromide114785625

Other    O
classical    O
benzodiazepines    O
include    O
chlordiazepoxide    O
,    O
clonazepam    O
,    O
lorazepam    O
,    O
oxazepam    O
,    O
nitrazepam    O
,    O
temazepam    O
,    O
flurazepam    O
,    O
bromazepam    B-Bromide114785625
,    O
and    O
clorazepate    O
.    O

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
less    O
than    O
24    O
hours    O
include    O
alprazolam    O
,    O
bromazepam    B-Bromide114785625
,    O
brotizolam    O
,    O
flunitrazepam    O
,    O
loprazolam    O
,    O
lorazepam    O
,    O
lormetazepam    O
,    O
midazolam    O
,    O
nitrazepam    O
,    O
oxazepam    O
,    O
and    O
temazepam    O
.    O

Prifinium    B-Bromide114785625
bromide    I-Bromide114785625
is    O
an    O
antimuscarinic    O
.    O

RbBr    B-Bromide114785625
,    O

Chromium(III)    B-Bromide114785625
bromide    I-Bromide114785625
is    O
an    O
inorganic    O
compound    O
with    O
the    O
chemical    O
formula    O
CrBr3    O
.    O

Platinum(IV)    B-Bromide114785625
bromide    I-Bromide114785625
is    O
the    O
chemical    O
compound    O
composed    O
of    O
platinum    O
and    O
bromine    O
with    O
the    O
formula    O
PtBr4    O
.    O

;    O
Thallium(I)    B-Bromide114785625
bromide    I-Bromide114785625

Strontium    B-Bromide114785625
bromide    I-Bromide114785625
is    O
a    O
chemical    O
compound    O
with    O
a    O
formula    O
SrBr2    O
.    O

ZnBr2    B-Bromide114785625
,    O

Older    O
hot    O
cells    O
used    O
a    O
ZnBr2    B-Bromide114785625
solution    O
in    O
a    O
glass    O
tank    O
to    O
shield    O
against    O
high    O
-    O
energy    O
gamma    O
rays    O
.    O

fazadinium    B-Bromide114785625
bromide    I-Bromide114785625
(    O
INN    O
)    O

Vecuronium    B-Bromide114785625

Vecuronium    B-Bromide114785625

The    O
"    O
mono"-    O
and    O
"    O
bis    O
"-    O
quaternary    O
azasteroid    O
series    O
of    O
compounds    O
to    O
which    O
candocuronium    O
belongs    O
are    O
based    O
on    O
the    O
same    O
principle    O
that    O
led    O
to    O
aminosteroids    O
such    O
as    O
pancuronium    B-Bromide114785625
,    O
vecuronium    B-Bromide114785625
and    O
rocuronium    O
:    O
use    O
of    O
the    O
steroid    O
skeleton    O
to    O
provide    O
a    O
somewhat    O
rigid    O
distance    O
between    O
the    O
two    O
quaternary    O
ammonium    O
centers    O
,    O
with    O
appendages    O
incorporating    O
fragments    O
of    O
choline    O
or    O
acetylcholine    O
.    O

In    O
2017    O
,    O
McKesson    O
was    O
involved    O
in    O
a    O
number    O
of    O
lawsuits    O
against    O
the    O
state    O
of    O
Arkansas    O
over    O
the    O
supply    O
of    O
vecuronium    B-Bromide114785625
bromide    I-Bromide114785625
.    O

Vecuronium    B-Bromide114785625

Selenium    B-Bromide114785625
oxybromide    I-Bromide114785625
(    O
SeOBr2    O
)    O
is    O
a    O
selenium    O
oxohalide    O
chemical    O
compound    O
.    O

It    O
proved    O
to    O
be    O
far    O
less    O
reactive    O
than    O
the    O
other    O
nitrogen    O
trihalides    O
nitrogen    O
trichloride    O
,    O
nitrogen    B-Bromide114785625
tribromide    I-Bromide114785625
and    O
nitrogen    O
triiodide    O
,    O
all    O
of    O
which    O
are    O
explosive    O
.    O


